Aptevo Therapeutics ( (APVO) ) has issued an update.
On March 20, 2025, Aptevo Therapeutics announced that two additional patients achieved remission within 30 days in Cohort 2 of their RAINIER Phase 1b trial for acute myeloid leukemia (AML), following the success of Cohort 1 where 100% of patients achieved remission. This development highlights the potential efficacy of Aptevo’s drug pipeline, particularly mipletamig, in improving patient outcomes in AML, positioning the company favorably within the oncology sector.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. operates in the biotechnology industry, focusing on developing bispecific antibody therapeutics for oncology. The company is engaged in creating clinical and preclinical drug candidates aimed at treating hematologic and solid tumor malignancies, with a market focus on high-value oncology indications.
YTD Price Performance: -42.45%
Average Trading Volume: 52,517
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.86M
See more insights into APVO stock on TipRanks’ Stock Analysis page.